PA5-82743

antibody from Invitrogen Antibodies

Targeting: FBN1 FBN, MASS, MFS1, OCTD, SGS, WMS

Provider product page for PA5-82743

Immunocytochemistry

Immunohistochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [1]
Comments [0]
Validations
Immunocytochemistry [1]
Immunohistochemistry [6]
Other assay [2]

Submit

Product number: PA5-82743 - Provider product page
Provider: Invitrogen Antibodies
Product name: Fibrillin 1 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Recombinant full-length protein
Description: Immunogen sequence: DVRPGYCYTA LTNGRCSNQL PQSITKMQCC CDAGRCWSPG VTVAPEMCPI RATEDFNKLC SVPMVIPGRP EYPPPPLGPI PPVLPVPPGF PPGPQIPVPR PPVEYLYPSR EPPRVLPVNV TDYCQLVRYL CQNGRCIPTP GSCRCEC
Reactivity: Human
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 0.1 mg/mL
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

FBN1 protein structure - PA5-82743 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of Fibrillin 1 in human cervix, uterine and cerebral cortex tissues using a Fibrillin 1 polyclonal antibody (Product # PA5-82743). Corresponding RNA-seq data are presented for the same tissues.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of Fibrillin 1 in human cervix, uterine using a Fibrillin 1 polyclonal antibody (Product # PA5-82743). The analysis shows moderate extracellular space positivity.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of Fibrillin 1 in human fallopian tube using a Fibrillin 1 polyclonal antibody (Product # PA5-82743). The analysis shows moderate extracellular space positivity.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of Fibrillin 1 in human testis using a Fibrillin 1 polyclonal antibody (Product # PA5-82743). The analysis shows moderate extracellular space positivity.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of Fibrillin 1 in human skin using a Fibrillin 1 polyclonal antibody (Product # PA5-82743). The analysis shows moderate extracellular space positivity.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of Fibrillin 1 in human cerebral cortex using a Fibrillin 1 polyclonal antibody (Product # PA5-82743). The analysis shows no positivity as expected.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 3 FBN1 identified as a novel substrate for FBXO2. (A,B) Cluster analysis and volcano plot of the differential proteins regulated by FBXO2 ubiquitination based on the LC MS/MS data. (C) FBN1 protein was directly bound to FBXO2 protein. (D) The intersection of IP-MS, LC MS/MS, and our RNA sequencing data. (E) FBN1 mRNA expression measured by RT-PCR in RL95-2-shFBXO2 and Ishikawa-ovFBXO2 cells compared with their parental cells ( P > 0.05). *** P < 0.001, t -test. (F) Endogenous FBXO2 and FBN1 protein levels in RL95-2 and Ishikawa cells. (G) FBN1 protein levels as measured by western blot analysis in shFBXO2-RL95-2 cells and Ishikawa-ovFBXO2 cells compared with their parental cells. (H) Immunohistochemical staining of FBXO2 and FBN1 in 90 EC samples and paired para-carcinoma samples. Left four photographs: FBXO2 was highly expressed in carcinoma tissues (upper panel), while FBN1 showed low expression in the same patient (lower panel). Right four photographs: FBXO2 showed low expression in carcinoma tissues (upper) while FBN1 was highly expressed in the same patient (lower). Original magnification, x60 and x400; scale bar: 200 and 50 mum, respectively. (I) Inverse correlation between FBXO2 and FBN1 staining, Pearson r = -0.305, P = 0.004. (J) Exogenous FBXO2 and FBN1 proteins interacted with each other in HEK-293T cells. HEK-293T cells were transfected with Flag-FBXO2, Myc-FBN1, and co-transfected with Flag-FBXO2 and Myc-FBN1 for 48 h, respectively. After treatment with 20

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 7 (A-L) Verification of differential genes associated with the cell cycle and autophagy signaling pathways. (A) mRNA levels of MCM7, CDK4, CCND1, SMAC1A, CCND2, CHEK1, CDC14B, and CCNA1 in RL95-2-NC and RL95-2-shFBXO2 groups. CDK4, CCND1, CCND2, and CCNA1 were significantly down-regulated in the RL95-2-shFBXO2 group compared with RL95-2-NC group. Data are presented as mean +- SD, ** P < 0.01, t -test. (B) mRNA levels of PPP2CA, ATG4A, ATG4B, ATG4C, and ATG4D in the RL95-2-NC and RL95-2-shFBXO2 groups. ATG4A and ATG4D were significantly up-regulated in the RL95-2-shFBXO2 group compared with the RL95-2-NC group. Data are presented as mean +- SD, ** P < 0.01, *** P < 0.001, t -test. (C) Protein levels of CDK4, CyclinD1, CyclinD2, and CyclinA1 in RL95-2-NC, RL95-2-shFBXO2, RL95-2-shFBN1, RL95-2-shFBXO2/shFBN1, and RL95-2-ovFBN1 cells. Knockdown of FBXO2 and overexpression of FBN1 revealed the same tendency in decreasing protein levels of CDK4, CyclinD1, CyclinD2, and CyclinA1 compared with the RL95-2-NC group. Knockdown of both FBXO2 and FBN1 showed increased protein levels of CDK4, CyclinD1, CyclinD2, and CyclinA1 compared with the RL95-2-shFBXO2 group. alpha-Tublin was used as a loading control. (D) The autophagy-specific inhibitor 3-MA (2 mM) reversed the effects of FBXO2 on the RL95-2 cells proliferation. Data are presented as mean +- SD, * P < 0.05, ** P < 0.01, one-way ANOVA. (E) The CDK4/6 inhibitor palbociclib (2 muM) reversed the effects of FBXO2 on the Ishikawa c